aavantgarde_logo.jpg
AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B at FLORetina 2024
09. Dezember 2024 02:00 ET | AAVantgarde Bio
AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa USH1B
aavantgarde_logo.jpg
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting
03. Dezember 2024 02:00 ET | AAVantgarde Bio
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting